The Janssen Pharmaceutical Companies of Johnson & Johnson announced new analyses from the Phase 3 MAIA study of Darzalex in combination with lenalidomide and dexamethasone, evaluating progression-free survival, or PFS, minimal residual disease, or MRD, negativity and overall response rate, or ORR, at a median follow-up of 64.5 months, and overall survival, or OS, at a median follow-up of 73.6 months in newly diagnosed, transplant-ineligible patients with multiple myeloma, regardless of patients’ age and across clinically important subgroups, as well as health-related quality of life among frail TIE patients. These findings, presented in oral and poster presentations at the American Society of Hematology 2022 Annual Meeting, "strengthen previous data from the MAIA study across clinically relevant study endpoints and patient populations," the company stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on JNJ:
- Johnson & Johnson price target raised to $205 from $198 at Citi
- Janssen submits BLA for talquetamab for RRMM to FDA
- Cantor Fitzgerald pharma/biotech analysts hold a dinner
- Cantor Fitzgerald pharma/biotech analyst hold a luncheon
- Horizon Therapeutics price target raised to $110 from $90 at Piper Sandler